HJFMRI supports the Kenya Medical Research Institute (KEMRI) in clinical research to test and advance malaria vaccines.

Most recently, the Mal 094 study was conducted in Western Kenya as a Phase 2b trial to study the efficacy, safety and immunogenicity of the world’s first malaria vaccine, RTS,S/AS01E. HJFMRI provided day-to-day research operations support for this malaria vaccine research and ensured safe, uninterrupted continuance of research in the face of COVID-related challenges and restrictions.